Buprenorphine depot - Indivior

Drug Profile

Buprenorphine depot - Indivior

Alternative Names: Atrigel buprenorphine; Depot buprenorphine; RBP-6000

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior
  • Class Cyclopropanes; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Nociceptin receptor agonists; Opioid delta receptor antagonists; Opioid kappa receptor antagonists; Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Opioid abuse

Most Recent Events

  • 01 Sep 2017 Indivior announces intention to appeal court ruling by the District Court of Delaware over ANDA litigation
  • 31 Jul 2017 Buprenorphine depot - Indivior receives priority review status for Opioid abuse in USA
  • 31 Jul 2017 FDA assigns PDUFA action date of 30/11/2017 for Buprenorphine depot - Indivior for Opioid abuse
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top